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A B S T R A C T
Decades of focus on selective ion channel blockade has been dismissed as an effective approach to antiar-
rhythmic drug development. In that context many older antiarrhythmic drugs lacking ion channel selectivity
may serve as tools to explore mixed ion channel blockade producing antiarrhythmic activity. This study in-
vestigated the non-clinical electrophysiological and antiarrhythmic actions of bisaramil and penticainide using in
vitro and in vivomethods. In isolated cardiac myocytes both drugs directly block sodium currents with IC50 values
of 13μM (bisaramil) and 60μM (penticainide). Both drugs reduced heart rate but prolonged the P–R, QRS and
Q–T intervals of the ECG (due to sodium and potassium channel blockade) in intact rats. They reduced cardiac
conduction velocity in isolated rat hearts, increased the threshold currents for capture and fibrillation (indices of
sodium channel blockade) and reduced the maximum following frequency as well as prolonged the effective
refractory period (indices of potassium channel blockade) of electrically stimulated rat hearts. Both drugs re-
duced ventricular arrhythmias and eliminated mortality due to VF in ischemic rat hearts. The index of cardiac
electrophysiological balance (iCEB) did not change significantly over the dose range evaluated; however, dif-
ferent drug effects resulted when changes in BP and HR were considered. While bisaramil is a more potent
sodium channel blocker compared to penticainide, both produce a spectrum of activity against ventricular ar-
rhythmias due to mixed cardiac ion channel blockade. Antiarrhythmic drugs exhibiting mixed ion channel
blockade may serve as tools for development of safer mixed ion channel blocking antiarrhythmic drugs.
1. Introduction
More than 500,000 deaths occur annually in the United States from
sudden cardiac death (SCD) and 60–70% result primarily from ven-
tricular arrhythmias due to coronary heart disease (CHD) [1–3]. CHD
remains the leading cause of death attributed to cardiovascular disease
[2,4] and remains the principal focus of health care providers [5,6].
While pharmacological treatment of ventricular arrhythmias does not
improve survival to hospital discharge; the use of antiarrhythmic drugs
such as lidocaine and amiodarone improve patient survival to hospital
admission [7,8].
Several classes (I-IV) of antiarrhythmic drugs exist and each act by
specifically removing a putative cause of the arrhythmia [9–11]. Class I
sodium channel blocking antiarrhythmic drugs (i.e., lidocaine) suppress
undesired ventricular automaticity, reduce abnormal cardiac conduc-
tion and prevent the development of arrhythmogenic re-entrant circuits
[12]. Although some class I antiarrhythmics prevent arrhythmia de-
velopment, others may precipitate fatal ventricular arrhythmias
[13–15].
Drug induced blockade of cardiac sodium channels is highly de-
pendent on the structural nature of the molecule [9]. While the ma-
jority of drugs in this class originate as local anaesthetics and are
analogs of lidocaine, many other structurally distinct drugs such as
flecainide were also developed with potent, selective sodium channel
blocking activity [16]. Similarly, other drugs such as the class III an-
tiarrhythmic drug, amiodarone, were developed which have mixed,
rather than selective, ion channel blocking actions. This means that
although amiodarone blocks repolarizing ventricular potassium chan-
nels, it also blocks sodium channels when given at high doses [17]
Amiodarone is a highly effective antiarrhythmic drug [18] and listed as
an essential medicine by the World Health Organization.
Bisaramil (YUTAC®) is structurally related to the alkaloid
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antiarrhythmic drug sparteine and shows efficacy against both chemical
and ischemic ventricular arrhythmias [19–24]. Bisaramil reduces both
intraventricular conduction [25] and ventricular depolarization (Vmax)
[23,26] and also produces use-dependent block [26,27]. Pugsley &
Goldin [28] showed that bisaramil has potent, preferential cardiac so-
dium channel isoform blocking properties.
Penticainide is a class I antiarrhythmic agent and a 2-pyridyl-pen-
tanamide derivative that is chemically-related to disopyramide [29,30].
Penticainide blocks sodium currents [31], reduces Vmax of the cardiac
action potential [32] and exhibits antiarrhythmic drug activity [33,34].
Of the antiarrhythmic drugs available for characterization, this
study investigated the electrophysiological and antiarrhythmic actions
of the potent but highly structurally dissimilar sodium channel blocking
drugs bisaramil and penticainide. An evaluation of the effects of both
drugs on the index of cardiac electrophysiologic balance (iCEB), a novel
biomarker of cardiac arrhythmias, was conducted. The implications of
mechanistic differences in assessment of ion channel blocking profiles is
discussed in terms of the potential for the use of these drugs as tools in
the study of ion channel function and in the study of the mechanisms
responsible for the development of cardiac arrhythmias.
2. Materials
2.1. Animals and general animal surgical preparation
Male Sprague-Dawley rats (200–300 g; U.B.C. Animal Care Centre)
were used for all studies in Vancouver, Canada while male Wistar rats
(200–300 g) were used for all studies in Canberra, Australia. All studies
were conducted according Animal Care and Use Committee guidelines
at both research sites. All study design and animal ethics conformed to
the ARRIVE guideline [35] and a more recent guidance on experimental
design and analysis [36].
Rats were anesthetized with pentobarbital (60mg/kg, i.p.) and the
trachea was cannulated for artificial ventilation [37]. The body tem-
perature was maintained at 36 ± 1C using a heating lamp. The right
jugular vein was cannulated for drug administration, the left carotid
artery for blood pressure recording and the ECG was recorded by the
method of Penz et al. [37].
2.2. Isolated ventricular rat cardiac myocytes
Cardiac myocyte isolation was performed according to Pugsley &
Saint [27]. Heparinized, male rats were cervically dislocated. Hearts
were removed and washed in an oxygenated, cold, calcium-free Tyr-
ode's solution prior to aortic perfusion with a warmed (37 ± 1C) cal-
cium-free Tyrode's solution. The pH 7.4 Tyrode's solution contained
(mM): NaCl 134; TES (N-tris-(hydroxymethyl)methyl-2-amino ethane-
sulphonic acid) 10; KCl 4; NaH2PO4 1.2; MgCl2 1.2; glucose 11. After
thorough washing, the heart was perfused with Tyrode's solution con-
taining protease (0.10mg/mL, Sigma Type XIV), collagenase (1.0 mg/
ml, Worthington CLS II), 25 μM calcium and fetal calf serum (1.0 μg/
ml). After 40min the ventricles were removed, cut into pieces in the
calcium-Tyrode's solution and the cells dispersed. Cell suspensions were
centrifuged, washed (200μM calcium-Tyrode's solution), resuspended
(1mM calcium-containing Tyrode's solution) and plated onto glass
coverslips for use in studies.
2.2.1. Solutions and compounds
Electrophysiology studies were conducted at 22–24 °C in a pH 7.4
bath solution containing (mM): NaCl 70; TES 10; KCl 5.4; CaCl2 2;
cholineCl 60; CoCl2 5; CsCl 5; MgCl2 1.0; glucose 10. The pipette so-
lution for sodium currents contained (mM): CsF 140; TES 10; MgCl2 1;
K-EGTA 10; CaCl2 2; ATP-disodium 10 and was pH adjusted to 7.4 with
1.0M KOH. Sodium currents were evoked by a voltage-step from a pre-
pulse potential of −150mV to a potential of 0mV. The voltage step was
delivered at 6 s intervals
Bisaramil ([(1R,5S)-3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]
nonan-9-yl] 4-chlorobenzoate) (a gift from The Chemical Works of
Gedeon Richter, Budapest, Hungary) (Fig. 1A) and penticainide (2-[2-
[di(propan-2-yl)amino]ethyl]-4-methyl-2-pyridin-2-ylpentanamide) (a
gift from Sanofi Recherche, Montpellier, France) (Fig. 1B) were solu-
bilized in 0.9% saline prior to i.v. injection or dissolution in the in vitro
assay external bath solution. A 1.0 mL plexiglass bath was used for
voltage clamp studies and drugs superfused cells at a flow rate of
1–2ml/min.
2.2.2. Electrophysiological recording methods
Isolated myocytes were perfused with buffer but only quiescent,
rod-shaped cells were selected for use in studies. Borosilicate glass
electrodes (resistances 1–5M) were used. Currents were recorded
10min after whole-cell patch clamp was achieved [27] using an Ax-
opatch 200 A amplifier (Molecular Devices, Union City, CA). At the
time of data analysis, final capacitance and leak compensation was
conducted by subtraction of a 20mV hyperpolarizing current pulse.
Currents were filtered (5 kHz), sampled (10 kHz) and records saved on a
computer system hard drive.
2.3. Langendorff isolated rat hearts
Rat hearts were attached to a Langendorff perfusion cannula [38] at
an aortic pressure of 100mmHg. Carbogenated (5% CO2 in O2) Krebs-
Henseleit buffer (pH 7.4), at a temperature of 35 ± 1.5C, was used to
perfuse the heart. Left ventricular pressure was measured using a saline-
filled balloon and the maximum rate of pressure development (+dP/
dtmax) recorded using a model 7P20C Grass differentiator. Epicardial
silver-ball electrodes recorded the ECG. Bisaramil (1–16 μM) or penti-
cainide (2–64 μM) was perfused for 5min at each concentration into
each heart (n=5) and contractility and ECG measures recorded.
2.4. Hemodynamic and ECG measures in anesthetized rats
The dose-response effects of bisaramil and penticainide were
Fig. 1. The chemical structures of bisaramil [(1R,5S)-3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]nonan-9-yl] 4-chlorobenzoate (A) and penticainide 2-[2-[di(propan-2-
yl)amino]ethyl]-4-methyl-2-pyridin-2-ylpentanamide (B).
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examined in anaesthetised, ventilated rats (n=5 per group). Doses of
bisaramil (0.01–8.0 μmol/kg, i.v.) or penticainide (0.01–32 μmol/kg,
i.v.) were given and each dose was administered over a 2min period
with an inter-dose interval of 10min. Heart rate was determined from
the ReR interval of the ECG recorded using a Grass polygraph (Model
7D, Quincy, Mass., U.S.A.). The ECG intervals (P–R, QRS, and Q–T)
were measured directly from the ECG traces.
2.5. Electrical stimulation studies
Electrical stimulation of the left-ventricle of anesthetized rats was
conducted as described by Pugsley et al. [10]. Square-wave stimulation
was used to determine threshold current (it-μA) and pulse-width (tt-ms)
for induction of extrasystoles and ventricular fibrillation threshold (VFt-
μA) levels. The maximum following frequency (MFF-Hz) and effective
refractory period (ERP-ms) were also measured using this same pro-
cedure [39]. Doses of both bisaramil and pentacainide (1–4.0 μmol/kg,
i.v.) were administered over a 5min period.
2.6. Coronary artery occlusion studies
Rats were anesthetized, ventilated and the left carotid artery was
cannulated to determine serum potassium concentrations (Ionetics
Potassium Analyzer, Fountain Valley, CA) and blood pressure. A left
thoracotomy was produced, the heart exposed and a polyethylene oc-
cluder was placed around the left main coronary artery [10]. The chest
was closed and animals were monitored during a 30min post-surgical
recovery period.
Animals were given a random and blind infusion of either saline,
bisaramil (2.5 μmol/kg) or penticainide (5.0 μmol/kg). Blood pressure
and the ECG were recorded during drug infusion and a blood sample
(0.25mL) removed prior to coronary artery occlusion.
Blood pressure, the ECG, arrhythmias, heart rate and animal mor-
tality were monitored for 30min post-occlusion. Arrhythmias were
defined as ventricular premature beats (VPB), ventricular tachycardia
(VT) and ventricular fibrillation (VF) and used to derive an arryhythmia
score (AS) defined according to Curtis & Walker [40]. At the end of the
observation period another blood sample was taken. Hearts were re-
moved and perfused with cardiogreen dye (1.0mg/ml) to reveal the
coronary occluded zone (OZ). Studies were performed according to the
Lambeth Conventions [41].
2.7. Index of cardiac electrophysiologic balance (iCEB)
iCEB [42,43] is a non-invasive biomarker that has been shown to
determine the ratio of potassium to sodium channel blockade observed
using standard variables derived from the ECG (i.e., iCEB=QT/QRS).
Since both the QRS and QT intervals are dependent upon the rate of
contraction and changes in hemodynamics, iCEB was also normalized
to both heart rate (i.e., iCEB/HR) and blood pressure (i.e., iCEB/BP),
respectively.
2.8. Statistical analysis
Data is shown as the mean ± standard error of the mean (SEM) (for
n experiments). The NCSS statistical, graphics, and sample size software
was used to conduct statistical analyses at an -level of p < 0.05. An
analysis of variance (ANOVA) followed by the post hoc Duncan’s test
were used in all experiments except in arrhythmia studies where VPB
number was log10 transformed. Mainland’s contingency tables were
used to determine significance between drug arrhythmic groups and
control saline [44].
3. Results
3.1. Isolated ventricular rat cardiac myocytes
While both bisaramil and penticainide produced a concentration-
dependent reduction in sodium current in isolated rat myocytes, bi-
saramil was a more potent current blocker. The half-maximal sodium
current block (IC50) for bisaramil (n=3) was 13μM with a Hill coef-
ficient (nH) of 1.2. The IC50 for penticainide (n=3) was 60 μM with a
Hill coefficient of 1.05. The development of block was similar for both
drugs and occurred immediately upon the start of drug perfusion with
drug wash-out from block being much slower for both compounds
(Fig. 2 A, B).
3.2. Langendorff isolated rat hearts
At concentrations that reduced sodium current in isolated myocytes,
bisaramil (16μM) and penticainide (64μM) significantly reduced heart
rate by 35% and 32%, respectively (Table 1). Both bisaramil and pen-
ticainide also significantly reduced peak systolic pressure by ∼50%
compared to pre-drug values at the highest concentrations tested
(Table 1). In addition to a reduction in ventricular contractility, both
Fig. 2. Bisaramil (panel A) and penticainide (panel B) block of the sodium current in rat cardiac myocytes. Sodium currents were evoked at 6 s intervals and either
bisaramil (30μM) or penticainide (120μM) was added to the bath solution as indicated. The panel B inset shows the current amplitude in the absence (A) and presence
(B) of penticainide. The re-control current (C) is indistinguishable from the control current.
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bisaramil and penticainide significantly reduced conduction velocity by
77% and 48%, respectively (Table 1). Bisaramil significantly prolonged
the P–R interval (170%) compared to penticainide (70%); however,
both drugs equally prolonged the QRS width (52% and 58%) relative to
control (Table 1). Both drugs also significantly prolonged the Q–T in-
terval by 68% and 36%, respectively, at the highest concentrations
tested (Table 1).
3.3. Haemodynamic and ECG measures in anesthetized rats
In all vehicle control (n= 5) animals both blood pressure and heart
rate were stable for the dosing duration (Table 2). Bisaramil and pen-
tacainide dose-dependently reduced blood pressure and heart rate in
anesthetized rats; however, bisaramil showed a greater potency in
overall cardiodepressive actions compared to penticainide. At maximal
doses of 8 μmol/kg and 32 μmol/kg, respectively, bisaramil and penti-
cainide significantly reduced blood pressure by 50% and heart rate by
52%, respectively (Table 2).
ECG measures were also dose-dependently changed by bisaramil
and penticainide. At the highest doses administered, bisaramil sig-
nificantly prolonged the P–R interval by 46% whereas penticainide
significantly prolonged the P–R interval by 63% (Table 2). Both drugs
also significantly prolonged the width of the QRS interval. Bisaramil
produced a 72% increase in the QRS interval while penticainide pro-
duced an 86% increase at the highest doses given. These changes are
consistent with the evidence of sodium channel blockade in both
myocytes and isolated hearts (Table 2). However, both drugs also had
effects on cardiac repolarization. Bisaramil significantly prolonged the
Q–T interval by 38% while penticainide prolonged the Q–T interval by
36%. These effects are consistent with evidence of potassium channel
blockade in isolated hearts (Table 2). The vehicle control did not affect
any of the ECG measures over the duration of the experiment (Table 2).
Fig. 3A describes the iCEB values determined for each drug using the
ECG (i.e., iCEB=QT/QRS). The drug iCEB profiles were not easily
distinguished from each other (Fig. 3A); however, each drug followed a
distinct profile when normalized to changes in both blood pressure
(Fig. 3B) and heart rate (Fig. 3C). Importantly, the pressure and/or
heart rate normalized iCEB measures were not changed relative to
control over cumulative dose ranges examined in subsequent electrical
stimulation and ischemic arrhythmia studies.
3.4. Electrical stimulation studies
The patterns of bisaramil and penticainide effects on hemodynamic
measures in vivo and ECG measures from both in vitro and in vivo studies
indicate drug-induced block of both sodium and potassium channels
with differences in drug potency and efficacy. Drug effects on electrical
properties of the heart relevant to sodium and potassium channel
function were evaluated against electrically-induced arrhythmias in the
rat (Table 1). Both drugs significantly (0.01 μmol/kg to 4 μmol/kg)
increased thresholds for capture for the induction of ventricular ex-
trasystoles (it) and ventricular fibrillation (VFt), respectively. Both
drugs also significantly prolonged the effective refractory period (ERP),
an effect consistent with decreases in maximum following frequency
(MFF). The vehicle-control did not affect any of the stimulation-based
measures over the duration of the experiment. The effects of bisaramil
and penticainide on these electrical stimulation measures are shown at
the maximal cumulative doses tested (4 μmol/kg) in Table 3.
An analysis of drug effects on both ERP and MFF (measures that are
affected by potassium channel blockade) versus VFt (a measure affected
by sodium channel blockade) suggested that both drugs produced a
dose-related change in the ratio of ERP and MFF relative to VFt (Fig. 4 A
and B). However, the reductions in ERP/VFt and MFF/VFt (at the
highest dose of drug tested compared to pre-drug values) were greatest
for bisaramil at 4-fold and 21-fold, respectively, when compared to
values for penticainide which were 2-fold and 11-fold, respectively. In
contrast, while both drugs produced dose-related changes in the ratio of
ERP and MFF compared to the it variable (Fig. 5A and 5B), the reduc-
tions in ERP/it and MFF/it (at the highest dose of drug dose tested
compared to pre-drug values) were similar for bisaramil at 1.5-fold and
Table 1
The effect of bisaramil and penticainide on Langendorff isolated rat hearts.
Variable Bisaramil Penticainide
Pre-drug Post-drug (16 μM) Pre-drug Post-drug (64 μM)
Systolic Pressure (mmHg) 151 ± 7.0 69 ± 12* 153 ± 5.0 75 ± 12*
Conduction Velocity (m/s) 2.2 ± 0.1 0.5 ± 0.08* 2.3 ± 0.04 1.2 ± 0.15*
ECG Measures (ms)
P-R 65 ± 4.0 177 ± 10* 70 ± 4.0 119 ± 9.0*
QRS 31 ± 1.0 47 ± 2.0* 32 ± 0.8 49 ± 2.0*
Q-T 40 ± 1.5 67 ± 3.0* 40 ± 1.0 55 ± 3.0*
Values represent mean ± SEM. * Indicates that post-drug values are significantly different from pre-drug values (p < 0.05). Note the post-drug concentation data
for both drugs is shown at the highest concentrations perfused (16 μM for bisaramil and 64 μM for penticainide).
Table 2
The effect of bisaramil and penticainide on hemodynamic and ECG variables in anesthetized rats.
Variable Bisaramil Penticainide Vehicle
Pre-drug Post-drug (8 μmol/kg) Pre-drug Post-drug (32 μmol/kg) Pre-drug Post-drug
(0 μmol/kg)
Blood Pressure (mmHg) 116 ± 5 58 ± 8* 121 ± 7 60 ± 9* 118 ± 5 128 ± 9
Heart Rate (beats/min) 490 ± 12 235 ± 22* 475 ± 11 230 ± 17* 472 ± 15 470 ± 22
ECG Measures (ms)
P-R 58 ± 2 85 ± 3* 56 ± 2 91 ± 6* 60 ± 3 56 ± 1
QRS 29 ± 0.5 50 ± 2* 29 ± 2 54 ± 2* 30 ± 1 30 ± 1
Q-T 45 ± 3 62 ± 3* 44 ± 2 60 ± 5* 43 ± 2 40 ± 4
Values represent mean ± SEM. *Indicates that post-drug values are significantly different from pre-drug values (p < 0.05). Note although full dose-response curves
were determined for both drugs, to enable efficient summary, the post-drug dose data for both drugs is shown only at the highest doses tested (8 μmol/kg for
bisaramil and 32 μmol/kg for penticainide).
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9-fold, respectively, when compared to values for penticainide at 1.5-
fold and 7-fold, respectively.
3.5. Coronary artery occlusion studies
Occlusion of the left anterior descending (LAD) coronary artery
produced uniform occlusion zone sizes of 32 ± 5%–35 ± 6% of the
left ventricular mass in saline and drug treated animals. Changes in
serum potassium both pre- and post-occlusion were not different be-
tween treatment groups and ranged between 3.4 ± 0.6mM -
3.7 ± 0.8mM before ischemia developed and between 3.6 ± 0.8mM
- 3.9 ± 1.0mM at the end of the study period. Neither bisaramil or
penticainide reduced the incidence of VPB’s (Log VPB) (Table 4).
However, while bisaramil significantly reduced the occurrence of VT
and VF, the effects of pentacainide were limited only to a significant
reduction in the incidence of VF (Table 4). Since bisaramil reduced the
incidence of both VT and VF, this resulted in a significantly reduced AS
and abolition of VF-induced arrhythmia related mortality. While pen-
ticainide did not reduce VT incidence or AS, it did eliminate mortality
due to ischemia. Neither bisaramil or penticainide altered the
maximum elevation or time to maximum elevation of the ST segment of
the ECG and neither drug reduced the increase in R wave amplitude
associated with ischemia in occluded hearts (data not shown).
4. Discussion
‘Sudden death’ resulting from fatal ventricular arrhythmias remains
the most common cause of death in the U.S. [4,45]. The underlying
causes of arrhythmias are problematic to ascertain because they arise
acutely but are slow to develop as a result of slowly developing
atherosclerosis in coronary arteries. Non-clinical studies show that
death, resulting from VF, is the likely first symptom of an acute MI
episode. However, since clinical trials with Class I and Class III anti-
arrhytmic drugs were stopped due to unanticipated high incidence of
deaths in drug treatment groups [13,14], research efforts ceased for
ion-channel related antiarrhythmic drug development. Similarly, these
findings have seriously restricted the use of most approved antiar-
rhythmic drugs because of serious drug safety issues [4,46]. However,
the optimism for development of novel, clinically effective antiar-
rhythmic drugs with a better safety profile persists. Many reviews
Fig. 3. The dose-dependent effects of bisaramil (●), penticainide (⭕) and saline control (▾) on the index of cardiac electrophysiological balance, iCEB (A) in
pentobarbital anesthetized rats (n= 5). iCEB (= QT/QRS) reflects the balance and imbalance of ventricular depolarization (QRS duration) and repolarization (QT
interval). iCEB profiles for each drug were separated from each other but followed normalization to changes in blood pressure (B) and heart rate (C) in anesthetised
rats. Values were determined after completion of each dose. Saline control had no effect upon iCEB. *Indicates P < 0.05 for difference from saline control.
Table 3
The effect of bisaramil and penticainide on electrical properties of the heart in anesthetized rats.
Variable Bisaramil Penticainide Vehicle
Pre-drug Post-drug (4 μmol/kg) Pre-drug Post-drug (4 μmol/kg) Pre-drug Post-drug
(0 μmol/kg)
Threshold current for capture (it; μA) 59 ± 1 135 ± 10* 58 ± 1 160 ± 10* 58 ± 1 58 ± 9
Ventricular fibriliation threshold (VFt; μA) 84 ± 5 490 ± 20* 83 ± 7 375 ± 19* 81 ± 7 89 ± 21
Effective refractory period (ERP; ms) 46 ± 3 79 ± 7* 55 ± 2 112 ± 4* 46 ± 4 50 ± 4
Maximum following frequency (MFF; Hz) 18.4 ± 1.0 5.1 ± 1.1* 17 ± 0.2 6.5 ± 0.6* 17 ± 1 17 ± 0.2
Values represent mean ± SEM. *Indicates that post-drug values are significantly different from pre-drug values (p < 0.05). Note although full dose-response curves
were determined for both drugs, to enable efficient summary, only the post-drug dose data for both drugs is shown at the highest dose tested (4 μmol/kg).
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suggest that drugs with a wider spectrum of pharmacological activity,
i.e., that block multiple ion channels, may have the desired efficacy and
safety combination [47]. This approach was used to characterize the
safety profile of a novel fluoroquinolone antimicrobial drug [48]. An
examination of the non-clinical and clinical cardiovascular studies
conducted with JNJ-Q2 provided a safe cardiovascular profile with
comparable or reduced potential to prolong the QT interval compared
to moxifloxacin. The findings in this study reflect the importance of
sodium and calcium channel blocking activity in counterbalancing
drug-induced potassium channel blocking activity [48]. Currently this
concept is being evaluated through the Comprehensive in vitro Proar-
rhythmia Assay (CiPA) initiative for cardiovascular drug safety. In a
cross-pharmaceutical company consortium, drug safety scientists are
currently validating a mechanistic-based assessment of the proar-
rhythmic risk of drugs [49–51]. The blocking effects of a set of test
drugs on hERG (or IKr), calcium, and sodium currents will be de-
termined and findings will be subsequently integrated into a computer
model of the human cardiomyocyte to predict proarrhythmic risk [49].
If these validated methods predict the proarrhythmic potential of test
drugs these studies will likely be a supplement to current drug safety
pharmacology studies [50].
We characterized the antiarrhythmic and cardiac electro-
physiological profile of bisaramil and penticainide using a com-
plementary variety of validated non-clinical models. From the patterns
of effects observed from the in vitro and in vivo studies conducted, both
Fig. 4. The dose-dependent effects of bisaramil (●), penticainide (⭕) and saline control (▾) on the ratio of electrical stimulation measures of refractoriness in cardiac
muscle, the effective refractory period (ERP) and maximum following frequency (MFF) to ventricular fibrillation threshold (VFt) in pentobarbital anesthetized rats
(n=5). Both drugs dose-dependently decreased the ERP/VFt (A) and MFF/VFt (B) ratios while saline control had no effect. Values were determined after completion
of each dose. *Indicates P < 0.05 for difference from saline control.
Fig. 5. The dose-dependent effects of bisaramil (●), penticainide (⭕) and saline control (▾) on the ratio of electrical stimulation measures of refractoriness in cardiac
muscle, the effective refractory period (ERP) and maximum following frequency (MFF) to threshold current for induction of extrasystoles (it) in pentobarbital
anesthetized rats (n=5). Both drugs dose-dependently decreased the ERP/it (A) and MFF/it (B) ratios while saline control had no effect. Values were determined
after completion of each dose. *Indicates P < 0.05 for difference from saline control.
Table 4




Log VPB VT (%) VF (%) Arrhythmia
Score (AS)
Mortality (%)
Saline 1.9 ± 0.3 80 60 5.6 ± 2.0 60
Bisaramil (2.5) 2.1 ± 0.2 0* 10* 1.5 ± 0.4* 0*
Penticainide
(5.0)
2.5 ± 0.4 100** 0* 4.3 ± 1.2** 0*
The antiarrhythmic properties of bisaramil and penticainde on arrhythmia in-
cidence during coronary artery occlusion (n=5/group). Arrhythmias were
recorded as ventricular premature beats (VPB), ventricular tachycardia (VT)
and ventricular fibrillation (VF). Log VPB is the log10 transformation of the
number of VPB’s. Arrhythmia Score (AS) is defined in references provided in
Section 2.6 of the Methods. *Indicates P < 0.05 for difference from saline
control. **Indicates a significant difference between drug treatments.
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bisaramil and penticainide directly block sodium and potassium chan-
nels in the heart and may also block calcium channels. These mixed ion
channel blocking patterns are not uncommon with cardiac drugs and
were originally discerned by Vaughan-Williams [9].
In addition to ECG and blood pressure changes in vivo and ECG and
cardiac contractility changes in isolated Langendorff hearts, both drugs
significantly reduced ischemia-induced arrhythmia mediated mortality
and selectively reduced high frequency arrhythmias (i.e., VT and VF)
compared to low frequency arrhythmias (PVC). Previously, it was
suggested that sodium channel block with bisaramil and penticainide
primarily accounted for the antiarrhythmic properties of these drugs
[22,27,30,32,52–54]. Our data supports these observations [27,28,30]
but highlights the importance of the blockade of other channels in the
heart. Our studies show that drug changes in repolarization parameters
(Q–T, ERP, MFF) occur along with those that produce sodium channel
block (PR, QRS, Vmax, it, VFt). The potassium channel blocking actions
that occur are likely beneficial to sodium channel blockade alone at
conveying antiarrhythmic efficacy since slowed conduction due to so-
dium channel blockade is a defined cardiac safety liability [55]. This
effect has been described using iCEB, a novel non-invasive biomarker
that determines the ratio of sodium to potassium channel blockade
using both the QRS and QT intervals derived from the ECG (i.e.,
iCEB=QT/QRS) [42]. iCEB may provide a novel means with which to
determine the potential for development of drug-induced cardiac ar-
rhythmias in the non-clinical [42] and possibly clinical assessment of
drugs [43]. iCEB is increased with drugs that predispose to arrhythmias
such as torsade de pointes (TdP) and is decreased with drugs that
predispose to non-TdP mediated arrhythmias (i.e., VT/VF). For bisar-
amil and penticainide the iCEB pre-drug ratio values (QT/QRS) were
1.6 and 1.5, respectively. At the highest administered doses (i.e., 8 and
32 μmol/kg) the iCEB ratio values were reduced to 1.2 and 1.1, re-
spectively. From Lu et al. [42] drugs that only slightly change iCEB may
be safer than drugs that significantly increase or decrease iCEB; how-
ever, a greater evaluation of this novel index is needed. For instance,
both drugs examined in this study produced increases in the blood
pressure and heart rate adjusted iCEB but not at doses producing effects
on electrical stimulation variables or at doses that were shown to be
antiarrhythmic. It is possible that at higher doses producing greater
changes in iCEB that arrhythmia’s may occur; however, no arrhythmias
were observed in any of the animals not subjected to coronary artery
occlusion or electrical stimulation.
The inward sodium current responsible for Phase 0 depolarization
(Vmax) of the action potential is blocked by both bisaramil and penti-
cainide. Drugs interact in a voltage- and time-dependent manner with
the sodium channel [55]. Drug associated channels produce shifts in
channel kinetics and are manifest as changes in the voltage-dependence
of inactivation [55,56]. Bisaramil produces a hyperpolarizing shift the
inactivation curve for the sodium current suggestive of a drug asso-
ciation with the inactive state of the channel [27,28]. Our current
findings indicate that the onset to block and recovery from block oc-
curred rapidly and thus bisaramil may have an affinity for the active
(open) channel [27]. Such effects are frequently observed with drugs
such as quinidine, a class Ia antiarrhythmic drug [56,57]. Examination
of the VFt data suggests that bisaramil is frequency-dependent since a
marked increase in the fibrillation threshold was observed as was a
reduction in the ratio of ERP/VFt and MFF/VFt (e.g., enhanced dose-
related effect on VFt over measures of repolarization). The effect of
penticainide on VFt was less pronounced at equivalent maximal doses
as was the reduction in ERP/VFt and MFF/ VFt despite very similar
profiles for dose-related changes in ERP/it and MFF/it and reductions in
these ratios for both drugs. Taken together these results suggest that
while both drugs may have had a similar ability to prevent the trig-
gering of ventricular arrhythmia’s at a given level of refractoriness (i.e.,
log VPB, ERP/it), the apparently greater frequency dependent actions of
bisaramil may have permitted for an enhanced ability of the drug to
prevent arrhythmia degeneration of the incidence of VT to fatal VF.
Bisaramil prolongs both ERP and APD in guinea pig myocytes
[19,20]. Paróczai & Kárpáti [20] showed that bisaramil prolonged
ventricular conduction time and ERP and slowed atrioventricular con-
duction time. This effect is reflected as a prolongation of the P–Q in-
terval of the ECG and suggests drug-induced calcium channel blockade.
Sunami et al. [26] found that bisaramil directly blocked the cardiac
calcium current. Clinically, bisaramil at a high dose (150mg) prolonged
the P–Q, QRS, and Q–T intervals of the ECG and reduced the rate of
development of supraventricular tachycardias [58] confirming an effect
on calcium channels.
Penticainide reduced cardiac Vmax and slowed cardiac conduction in
a concentration, voltage and rate-dependent manner [29,31]. While
both Carmeleit [30] and Coraboeuf et al. [59] showed that penticainide
reduced automaticity and blocked multiple cardiac currents, Sassine
et al. [60] showed that penticainide inhibited the slow inward calcium
current. Clinically, penticainide produces a negative inotropic effect
[61], prevents reentrant tachycardia [62] and markedly affects depo-
larization and repolarization in patients with ventricular arrhythmias
[63].
Thus, blockade of cardiac sodium current occurs primarily for bi-
saramil and penticainide; however, these drugs also block potassium
(and likely calcium) currents which provides for a more balanced
blockade of both inward and outward currents supporting antiar-
rhythmic, not proarrhythmic, activity. This balanced ion channel
blockade, reflected by the minimal changes in the iCEB biomarker,
limits the potential for the development of severe adverse events as-
sociated with sodium channel blockade alone which has been asso-
ciated with increased mortality in patients [55]. The data obtained from
the use of the iCEB biomarker could be the basis for the conduct of
additional validation studies that assess the relationship between drug-
induced sodium channel block, slowed conduction and pro-arrhythmic
liability associated with these drug effects. Methodical comparisons
between pure ion channel blocking drugs and drugs with mixed ion
channel blocking properties using validated assays are also needed to
complement the ongoing CiPA initiative. Proarrhythmic liability re-
sulting from sodium channel blockade and mechanisms responsible for
the developed arrhythmia will require the equivalent level of in-
vestigation that was used for drug-induced QT prolongation. Now that
drug safety scientists have eradicated drug-related hERG signals from
their drug discovery pipelines, drug effects on cardiac conduction may
take on a more prominent role in the non-clinical evaluation of cardiac
liabilities.
5. Conclusion
This study compared the antiarrhythmic and electrophysiological
actions of bisaramil and penticainide, using in vitro and in vivomethods.
Both drugs altered ECG measures indicative of sodium channel
blockade (QRS interval) but also potassium (QT interval) and likely
calcium channel blockade (P–R interval). In isolated hearts, both bi-
saramil and penticainide reduced conduction velocity but prolonged
the Q–T interval of the EKG. In electrical stimulation studies both drugs
increased indices of sodium and potassium channel blockade and were
antiarrhythmic. In ischemic ventricular arrhythmias at doses exhibiting
sodium and potassium channel blockade, both drugs significantly re-
duced the incidence and mortality due to ischemic arrhythmias. iCEB
values did not change significantly over the dose range evaluated;
however, drug separation occurred when changes in BP and HR were
considered. In totality, these findings indicate that both bisaramil and
penticainide are antiarrhythmic and produce a spectrum of activity in
the heart indicative of mixed ion channel blocking effects.
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